Friday, April 30, 2010

Dendreon gains FDA approval for prostate cancer drug Provenge

FDA Approves PROVENGE(R) for the Treatment of Men with Advanced Prostate Cancer

SEATTLE, April 29, 2010 /PRNewswire via COMTEX/ --Dendreon Corporation (Nasdaq: DNDN) today announced that the U.S. Food and Drug Administration (FDA) has approved PROVENGE(R) (sipuleucel-T), an autologous cellular immunotherapy for the treatment of asymptomatic or minimally symptomatic metastatic, castrate-resistant (hormone-refractory) prostate cancer (CRPC). PROVENGE is designed to induce an immune response against prostatic acid phosphatase (PAP), an antigen expressed in most prostate cancers, and is the first in a new therapeutic class known as autologous cellular immunotherapies.

Keep Reading at: http://investor.dendreon.com/phoenix.zhtml?c=120739&p=irol-newsArticle&ID=1420143&highlight=

Two BIO Super Sessions Available Via Live Webcast

Looking forward to a fantastic BIO International Convention next week!
http://convention.bio.org

If you can't make it, we have two of the Super Sessions available via webcast - Ernst & Young and Burrill Sign up for Monday, May 3 or Tuesday, May 4th or both.

Wednesday, April 21, 2010

 Breakout Sessions: Enhanced. Engaging. Enriching.

BIO International Convention attendees can expect 125 sessions across 17 tracks, including business development, health care, industrial, environmental, and food and agriculture. And new this year: Look for Advanced Sessions, Hot Topics, Marketplace Watch, Sessions with CLE Credits and much more! View a full list of breakout sessions at http://r.smartbrief.com/resp/vAmkjYmetfxijOCicOdoCicNwrUe

BIO Convention Super Sessions will present info on the latest industry trends

Hear high-level discussions on the topics and trends that matter most in the biotechnology industry. The topics will include global biotech innovation; the industry's worldwide performance; a state-of-the-industry report; advancing regulatory science; and a survey on biotech and pharma partnering. See the complete list of Super Sessions at http://r.smartbrief.com/resp/vAmkjYmetfxijrCicOdoCicNoJob

Monday, April 12, 2010

GaBio To Hold Gubernatorial Candidate Forums in May

ATLANTA (April 12, 2010) – Life sciences economic development, science education in k-12 schools and the impact of federal health care reform will be the major topics of discussion at Democratic and Republican gubernatorial candidate forums in May organized by Georgia Bio (GaBio) and hosted by Kennesaw State University’s (KSU) College of Science and Mathematics.

“These forums will give Georgia’s gubernatorial candidates an opportunity to address three issues that are critical to our state’s future: the significance of high-paying, advanced technology job growth; the importance of science and math education; and the impact of federal health care reform,” said Charles Craig, Georgia Bio President.

“Kennesaw State is honored to partner with Georgia Bio in hosting what we expect to be a lively exchange of ideas on critical topics,” said Laurence I. Peterson, dean of KSU’s College of Science and Mathematics. “The debates will spotlight the important life sciences profession, as well as issues that matter to the students, faculty and staff within our college and the community at large. We look forward to welcoming the gubernatorial candidates and special guests to KSU for these important events.”

KEEP READING AT http://www.gabio.org/pr_details.aspx?subid=323

Monday, April 5, 2010

U.S. Surgeon General to Speak at 2010 BIO International Convention

WASHINGTON, DC – United States Surgeon General Regina Benjamin, M.D., will deliver a keynote address at the 2010 BIO International Convention May 3-6, in Chicago. The May 3 Biotechnology Summit will focus on the importance of integrating diverse and underserved populations within the medical, agricultural and energy research industry; increasing employment opportunities and encouraging participation in clinical trials. The Surgeon General’s address will begin at noon.

Keep Reading: http://www.gabio.org/pr_details.aspx?subid=320&refid=8